SynGEM®

The human respiratory syncytial virus (RSV) is a major cause of seasonal epidemics of severe lower respiratory tract disease. Worldwide an estimated 64 million RSV infections occur annually, resulting in the death of approximately 160,000 individuals. While RSV attacks all age groups, the most severe disease occurs in (i) the elderly, (ii) patients with chronic lung disease, (iii) persons with impaired immunity and (iv) very young infants (≤2 years of age). There is currently no vaccine available to prevent disease caused by RSV.

Our candidate vaccine SynGEM® is an RSV subunit vaccine based on the validated bacterium-like-particle (BLP) based Mimopath® technology carrying F proteins. The BLP technology allows presentation of stabile native trimeric F proteins that elicit locally secreted IgA in the mucosal layers and a balanced Th1/Th2-type of systemic immune responses that are protective. It will be developed at first instance for the elderly, adults at risk and children, and potentially at a later stage for infants.

syngem

 

15.04.14 Mucosis announces a strategic partnership with Changchun BCHT Biotechnology of China and raises additional capital
more >

12.08.13 Mucosis announces publication of data demonstrating safety and protection by mucosally administered Mimopath®-based prefusion-like F RSV vaccines
more >

16.05.13 Mucosis presents preclinical data demonstrating protection by its intranasal SynGEM® RSV vaccine candidate
more >

08.10.12 Mucosis signs Research and License Option Agreement with Crucell
more >

25.09.12 ExpreS²ion, Mucosis, and University of Copenhagen receive Eurostars grant
more >

18.09.12 Mucosis Appoints Thomas Johnston to CEO
more >